Birch Hill Investment Advisors LLC Lowers Stock Position in Kenvue Inc. $KVUE

Birch Hill Investment Advisors LLC decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 66.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,158 shares of the company’s stock after selling 41,330 shares during the quarter. Birch Hill Investment Advisors LLC’s holdings in Kenvue were worth $365,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Salomon & Ludwin LLC acquired a new position in shares of Kenvue during the 3rd quarter valued at $25,000. NBT Bank N A NY lifted its holdings in shares of Kenvue by 180.3% during the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after acquiring an additional 1,006 shares in the last quarter. Cornerstone Planning Group LLC lifted its holdings in shares of Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after acquiring an additional 1,361 shares in the last quarter. Golden State Wealth Management LLC lifted its holdings in shares of Kenvue by 150.1% during the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after acquiring an additional 1,190 shares in the last quarter. Finally, Trust Co. of Vermont lifted its holdings in shares of Kenvue by 50.9% during the 3rd quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $17.61 on Monday. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. The firm has a market capitalization of $33.80 billion, a P/E ratio of 22.86, a P/E/G ratio of 4.00 and a beta of 0.61. The company’s fifty day moving average price is $17.92 and its two-hundred day moving average price is $17.11.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The firm had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. During the same quarter in the previous year, the business posted $0.26 EPS. The firm’s revenue was up 3.2% compared to the same quarter last year. On average, research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th were issued a $0.2075 dividend. The ex-dividend date was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a yield of 4.7%. Kenvue’s payout ratio is currently 107.79%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on KVUE. Jefferies Financial Group lowered shares of Kenvue from a “buy” rating to a “hold” rating and reduced their target price for the company from $23.00 to $18.00 in a report on Friday, January 30th. Barclays reduced their target price on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. Citigroup reduced their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, April 15th. Canaccord Genuity Group lifted their target price on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a report on Wednesday, April 8th. Three research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. Based on data from MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and an average target price of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.